BFM
LVTX

Boothbay Fund Management’s LAVA Therapeutics LVTX Stock Holding History

Boothbay Fund Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,358
Closed -$109K – 2077
2021
Q3 		$109K Buy
+18,358
New +$132K ﹤0.01% 1784

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Boothbay Fund Management's LVTX Position: Q4 2021 in Review

Boothbay Fund Management sold out of LAVA Therapeutics (LVTX) in Q4 2021, closing a stake of 18,358 shares — an estimated $109K sold.

Boothbay Fund Management first reported a position in LVTX in Q3 2021 and held it in 1 quarter. The position peaked at $109K in Q3 2021. 20 funds tracked by Wall St. Rank hold LVTX as of Q4 2021.

  • Boothbay Fund Management reported no remaining LAVA Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 18,358 LAVA Therapeutics shares in Q4 2021, an estimated $109K.
  • Boothbay Fund Management first reported a position in LAVA Therapeutics in Q3 2021 and held it in 1 quarter.
  • Boothbay Fund Management's LAVA Therapeutics position peaked at $109K in Q3 2021.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.